Psychedelics
Mind-altering substances like psilocybin, LSD, MDMA, and ayahuasca and their therapeutic and cultural use.
83 claims·1 news story
The U.S. Food and Drug Administration has opened a public docket seeking feedback by November 20, 2026 on trial design, dose selection, patient eligibility, safety monitoring, and oversight for clinical trials of ibogaine.
The FDA opened a public docket seeking feedback by November 20, 2026 on trial design, dosing, patient eligibility, and safety monitoring for ibogaine studies.
552c7ae14Topic
FDA ibogaine clinical trials
First government-funded clinical trials of ibogaine for opioid addiction and PTSD, conducted by the FDA and VA.
13 claims·1 news story